Pacira Pharmaceuticals, Inc. Release: Two New Studies Support Use of EXPAREL Via Infiltration Into the Transversus Abdominis Plane for Postsurgical Pain Control

Published: May 07, 2013

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

PARSIPPANY, N.J.--(BUSINESS WIRE)--Pacira Pharmaceuticals, Inc. (NASDAQ: PCRX) today announced findings from two new studies supporting the use of EXPAREL® (bupivacaine liposome injectable suspension) infiltrated into the transversus abdominis plane for postsurgical pain management. Infiltration into the transversus abdominis plane (or iTAP) is being increasingly utilized for postsurgical analgesia during upper or lower abdominal procedures for up to 72 hours of postsurgical analgesia with a non-opioid, local anesthetic.

Help employers find you! Check out all the jobs and post your resume.

Back to news